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Abstract
In neuroinflammatory disorders such as multiple sclerosis, the physiological function of the blood-brain barrier (BBB)
is perturbed, particularly in demyelinating lesions and supposedly secondary to acute demyelinating pathology. Using
the toxic non-inflammatory cuprizone model of demyelination, we demonstrate, however, that the onset of persistent
BBB impairment precedes demyelination. In addition to a direct effect of cuprizone on endothelial cells, a plethora of
inflammatory mediators, which are mainly of astroglial origin during the initial disease phase, likely contribute to the
destabilization of endothelial barrier function in vivo. Our study reveals that, at different time points of pathology and
in different CNS regions, the level of gliosis correlates with the extent of BBB hyperpermeability and edema.
Furthermore, in mutant mice with abolished type 3 CXC chemokine receptor (CXCR3) signaling, inflammatory
responses are dampened and BBB dysfunction ameliorated. Together, these data have implications for understanding
the role of BBB permeability in the pathogenesis of demyelinating disease.
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Introduction
The cerebral vasculature controls and restricts the trans-
port of biomolecules between blood and the CNS paren-
chyma by means of the blood-brain barrier (BBB) [1, 37].
While specialized brain endothelial cells are physically
connected via unique belt-like tight junctions that mediate
BBB tightness, perivascular cells and astrocytes also con-
tribute to BBB physiology, collectively forming the neuro-
vascular unit (NVU). In a wide range of neurological
disorders including multiple sclerosis (MS) increased vas-
cular permeability has been observed [33] but the primary
cause for the pathophysiology of the NVU and the relation
to disease specific pathomechanisms remains unclear.
MS is an acquired inflammatory demyelinating disease
of the CNS in which BBB permeability is increased in
both newly forming demyelinating lesions and even in
normal appearing white matter [18, 59]. BBB impair-
ment is observed at the onset of clinical symptoms in
experimental autoimmune encephalomyelitis (EAE), an
animal model of MS, coinciding with initial immune cell
infiltration and glial activation [19, 51]. In this model,
pro-inflammatory cytokines/chemokines produced by
activated immune cells on the peripheral side of the bar-
rier, or by glial cells in the CNS, contribute to BBB
hyperpermeability [4, 42]. Thus, BBB disruption could
potentially be secondary to pathology. However, it is un-
clear whether demyelination or other disease factors
cause BBB disturbances.
We previously showed in the non-inflammatory cupri-
zone model of demyelination [45], that BBB permeability
is increased at the peak of demyelinating disease, and
that this BBB dysfunction can be utilized for CNS deliv-
ery of therapeutics [11]. However, it is unclear which
pathomechanism triggers the BBB breach in the cupri-
zone model. Here, we further characterize these BBB
disturbances, relating BBB pathophysiology to histopath-
ology in different brain regions and at different stages of
disease progression. We demonstrate that early disease
processes are associated with elevated levels of several
pro-inflammatory mediators of predominantly astroglial
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origin. This local inflammatory milieu, together with a
primary effect of cuprizone on endothelial cells, leads to
the downregulation of BBB maintenance factors, endo-
thelial efflux transporters, and tight junction proteins
resulting in morphological disruption of tight junctions.
These endothelial disturbances are associated with local
hyperpermeability of the BBB and edema, even before
the onset of demyelination.
Materials and methods
Mice
All animal studies were performed in compliance with
the animal policies of the Max Planck Institute of Ex-
perimental Medicine, and were approved by the German
Federal State of Lower Saxony. Adult male C57BL/6N
mice or CX3CR1GFP/GFP mice [26] were taken at 8–
10 weeks of age. Animals were randomly assigned to an
experimental group. Cuprizone (0.2% w/w, Sigma) was
mixed into powder chow (V1124 ssniff ).
Histological analyses
Histological analyses were done as described [11, 49] with
minor modifications. Anesthetized mice were perfused
with paraformaldehyde (PFA) and brains were cut by
vibratome (40 μm, Leica VT1200)) or embedded in paraf-
fin. Brain sections (HMP 110, MICROM) at Bregma −1.58
were taken for histological characterization using standard
protocols using LSAB2 (Dako) or Vector Elite ABC (Vec-
tor Labs). For occludin and ZO1 staining, animals were
perfused with PFA containing 0.2% glutaraldehyde and cut
on a vibratome. Tissue sections or fixed endothelial cells
were processed for immunolabeling by permeabilization
(0.4% Triton X-100 in PBS), blocking (4% horse serum, 2%
BSA, 0.2% Triton X-100 in PBS) and incubation with first
antibody (1% HS, 0.05% Triton X-100 in PBS). Incubation
with fluorophore coupled secondary antibodies (Thermo-
Fisher) and DAPI (4′,6-diamidino-2 phenylindole) were
done in 1.5% HS in PBS, after which sections were
mounted in AquaPolymount (Polysciences). Gallyas silver
impregnation was done as described [49]. Specimens were
analyzed on an Axio Imager.Z1 (Zeiss) equipped with an
AxioCam MRc3, × 0.63 Camera Adaptor and the ZEN
2012 blue edition software using ×10 objective (Plan Apo-
chromat × 10/0.45 M27) or × 20 objective (Plan-Apochro-
mat × 20/0.8) or by confocal laser scanning microscopy
(Leica SP5 HCX PL APO CS 63×/1.20) using the Leica
Confocal Software (Leica Microsystems). Quantification of
positive areas in the corpus callosum above the fornix
were done by semi-automated analysis with ImageJ soft-
ware macro and color deconvolution plug-in. Vessel paint
was performed as described [34] with minor modifica-
tions. Mice were intravenously injected with 200 μl of
20 mg/ml FITC-Dextran (46,945, Sigma-Aldrich Inc.,
Germany). After 30 min circulation time animals were
anaesthetized, flushed, stained with DID (ThermoFischer,
D7757) and fixed with PFA before sectioning with a vibra-
tome (100 μm). All Images were processed with NIH Ima-
geJ and Adobe Photoshop CS5.1 software. Electron
microscopic analysis was done as previously described
[49]. Briefly, tissue was fixed in 4% PFA, 2.5% glutaralde-
hyde, 0.1 M Phosphate buffer and sagittal sections were
cut on a vibratome (Leica VT1200). The corpus callosum
with adjacent tissue was punched and embedded in epon
(LYNXII, EMS). Ultrathin uranyl acetate contrasted sec-
tions were imaged with a LEO EM912 AB (Zeiss)
equipped with a 2 k–CCD camera (TRS, Moorenweis).
Blood-brain barrier permeability
Tracer injections were done as described [11, 49] with
minor modifications. For measurement of BBB permeabil-
ity, tracers were i.v. injected (Evans blue 50 mg g-1 body
weight; sodium fluorescein 200 mg g-1 body weight). After
4 h incubation, animals were perfused with PBS to remove
tracer from the circulatory system. The region of interest
was dissected, and tissue samples were weighed. For
lyophilization, tissues were exposed to a shelf temperature
of −56 °C for 24 h under vacuum of 0.2 mBar (Christ
LMC-1 BETA 1–16). Samples were weighed for calcula-
tion of water content and edema. Lyophilized tissue sam-
ples were extracted with formamide at 57 °C for 24 h on a
shaker at 300 rpm (Eppendorf Thermomixer). Integrated
density of tracer fluorescence was determined in tripli-
cates after 1:3 ethanol dilution to increase sensitivity.
Tracer concentration was calculated using a standard
curve of tracer spiked brain samples.
Immunoblot
Brain tissue samples were lysed in sucrose buffer (18% su-
crose, 10 mM Tris/HCl pH 7.4, 1 mM sodium hydrogen
carbonate, 1 mM magnesium chloride, 0.1% Triton, 0.2%
lithiumdodecyl sulphate, 0.025% sodium deoxycholate)
with protease inhibition (Roche) using a Precellys 24
homogenizer (Bertin technologies). Detection of immuno-
labeled proteins was performed with ECL detection re-
agent (Perkin Elmer) using ChemoCam Imager (Intas).
Magnetic cell isolation
Glial cells were isolated according to the adult brain dis-
sociation protocol (Miltenyi biotec). Corpus callosum and
cortex were isolated using a brain matrix from Bregma
+1.10 to −2.46. Antibody labeling steps were done accord-
ing to the respective antibody Microbead kit protocol
(Miltenyi biotec), oligodendrocytes (O4, 130–096-670); as-
trocytes (ACSA-2, 130–097-679), microglia (CD11b, 130–
093-636), and endothelial cells (CD31, 130–091-935). Pur-
ity of cell populations was routinely determined by qPCR
on extracted and reverse transcribed RNA (see below) and
revealed only minimal contamination by other cell types.
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Cell cultures
Primary mouse brain endothelial cell cultures were
established from 7 days old mice or rats. Briefly, cortices
were digested with 1 mg/ml collagenase/dispase and
2.5 μg/ml DNAse (Roche) in dissection buffer (HBSS,
10 mM HEPES, 0.5% BSA, 5000 U/ml penicillin/strepto-
mycin) for 45 min at 37 °C. After trituration, cells were
resuspended in 25% BSA and centrifuged at 1000 g for
20 min to pellet microvessels. Isolated microvessels from
individual mice were plated in Endobasal Medium (Pro-
mocell) with 0.4% puromycin for positive selection on
coverslips or polyester transwell inserts (Corning). Pri-
mary astrocyte cultures were prepared from 0 to 2 days
old mice as previously described [11]. Primary microglia
cultures were prepared from P0-P2 old mice by differen-
tial shaking of mixed glial cultures as described [55]. Cell
purity was routinely determined by immune stainings
and always exceeded 95%. For coculture experiments,
endothelial cells cultured in transwell inserts above as-
trocytes plated on the bottom of the well plate. Conflu-
ent cells cultures were treated with a final concentration
of 250 μM cuprizone in 0.125% DMSO or in 0.125%
DMSO alone for up to 72 h. An epithelial Voltohmmeter
(EVOM2, World Precision Instruments) equipped with
Endohm-12 chamber electrodes was used to measure
transendothelial electrical resistance (TEER). Metabolic
activity was determined using a WST1 assay (Cayman)
according to the manufactures protocol, after exposure
to increasing concentrations of cuprizone (0–250 μM)
for up to 72 h, or 20 μM peroxide as positive control.
Expression analyses
Expression analyses were done as described [11]. For tis-
sue expression analyses, corpus callosum and cortex was
dissected from Bregma +1.10 to −2.46. RNA was extracted
using QIAshredder and RNeasy protocols (Qiagen). Con-
centration and quality of RNA was evaluated using a
NanoDrop spectrophotometer and RNA Nano (Agilent).
cDNA was synthesized with Superscript III (Invitrogen)
and quantitative PCRs were done in triplicates with the
GoTaq pPCR Master Mix (Promega) on a 7500 Fast Real-
Time PCR System (Applied Biosystems). Expression
values were normalized to the mean of two housekeeping
genes, HPRT (Hypoxanthin-Phosphoribosyl-Transferase
1) and Rplp0 (60S acidic ribosomal protein P), and quanti-
fication was done by applying the ΔΔCt method, normal-
ized to age matched untreated controls (set to 1). All
primers (Additional file 1: Table S1) were intron-spanning.
Antibodies
CAII (Said Ghandour), Olig2 (Charles Stiles/ John Al-
berta), GFAP (Chemicon), MAC3 (Pharmigen), Iba1
(Wako), PECAM1 (dianova), AQP4 (Santa Cruz), occlu-
din, ZO-1 and claudin-5 (Thermo Fisher), GAPDH
(Enzo). For generation of GLUT1 antisera, rabbits were
immunized with the C-terminal intracellular peptide
(CDKTPEELFHPLGADSQV). Anti-GLUT1 antibody was
purified by affinity chromatography.
Statistical analysis
Statistical analysis was performed using Prism software
(GraphPad Software), and results are presented as the
mean ± s.e.m.. Two-way ANOVA, one-way ANOVA and
two-tailed unpaired Student’s t tests were performed as
appropriate. Only P values <0.05 were considered statis-
tically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
Vascular permeability is increased at the peak of
cuprizone induced demyelination
At the peak of demyelination after 5 weeks of cuprizone
exposure, vascular permeability is increased as we
showed previously [11]. To explore potential causes for
this BBB instability, we performed a series of expression
analyses on dissected corpus callosum samples from
mice fed cuprizone for 5 weeks. As expected, histopath-
ology (Additional file 2: Figure S1a) was reflected in re-
duced expression of oligodendroglial genes, e.g. Olig2
(oligodendrocyte lineage transcription factor 2) and in-
creased expression of markers for gliosis (Gfap, glial fi-
brillary acidic protein; Aif1, allograft inflammatory factor
1, encoding Iba1) (Fig. 1a, Additional file 1: Table S2).
When we quantified the levels of inflammatory media-
tors that have previously been shown to induce BBB dys-
function [42, 47, 58], Tnf (tumor necrosis factor), Il1b
(interleukin 1 beta), and Ccl2 (C-C Motif Chemokine
Ligand 2) were strongly upregulated (Fig. 1b). Other fac-
tors such as Il2 (interleukin 2) and Ifng (interferon
gamma) remained unchanged compared to controls.
Notably, BBB impairment in the cuprizone model was
not associated with mRNA upregulation of HIF1α (hyp-
oxia induced factor 1 alpha), VEGF-A (vascular endothe-
lial growth factor A) or matrix metalloproteinases,
which are jointly associated with hypoxia-induced BBB
dysfunction in EAE and other disease models [5, 6] (not
shown). In contrast, mRNA abundance of the nitric
oxide synthases NOS2 and NOS3 was significantly in-
creased in cuprizone treated animals, implicating react-
ive nitrogen species likely mediators of BBB leakage.
Consistent with these findings, expression of endothelial
markers including genes encoding tight and adherens
junction proteins PECAM1 (platelet/endothelial cell ad-
hesion molecule 1/CD31, Pecam1 gene), claudin-5
(Cldn5), occludin (Ocln), ZO1 (Tjp1 gene), cadherin-1
(Cdh1), and cadherin-5 (Cdh5) were strongly downregu-
lated (Fig. 1a).
When we examined the morphology of the BBB by
transmission electron microscopy, cuprizone fed animals






Fig. 1 (See legend on next page.)
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often displayed a discontinuous electron-dense junctional
area with focally increased junctional width (Fig. 1c,
Additional file 2: Figure S2), implying that the physical bar-
rier of the BBB mediated by endothelial tight and adherens
junctions could be altered. This observation was confirmed
by immunofluorescence analysis of selected tight junction
proteins that showed strongly reduced staining intensity in
cuprizone fed animals (Fig. 1d–g). Increased BBB perme-
ability was demonstrated by extravasation of tracers such as
FITC-dextran (Fig. 1f, see also below). By electron micros-
copy we also observed locally split endothelial and astroglial
basement membranes, hypertrophic astrocytes, and spor-
adic endothelial cells with atypical ultrastructure in cupri-
zone fed animals (Fig. 1c, Additional file 2: Figure S2).
Moreover, while the number of blood vessels in the entire
cross-sectional area of the corpus callosum remained un-
changed, vessel density was strongly reduced (Fig. 1h), likely
caused by the tissue swelling due to the dramatic gliosis at
this time point (Additional file 2: Figure S1). Together,
these data show that the increased BBB permeability
at the peak of cuprizone induced demyelination coin-
cides with substantial upregulation of BBB-disrupting
pro-inflammatory mediators. This is associated with
strong downregulation of endothelial tight junction
proteins and morphological changes at the endothelial
barrier.
Cuprizone directly affects BBB permeability in vitro
We next explored whether cuprizone directly damages
cellular constituents of the NVU, namely mouse brain
endothelial cells or astrocytes, as observed for mature oli-
godendrocytes [10]. Using primary cultures of either cell
type in a WST1 assay that measures the activity of cellular
dehydrogenases, cuprizone did not affect metabolic activity
within 24 h, even when administered in concentrations up
to 500 μM (Additional file 2: Figure S3a, b). However, after
72 h incubation with 250 μM cuprizone, the WST1 signal
in endothelial cells decreased by about 14% compared to
vehicle treated cultures (Additional file 2: Figure S3c, d),
which were not caused by cell death but rather reflected
metabolic adaptations to the toxic cuprizone insult.
To investigate the effect of cuprizone on the barrier
function of endothelial cells in more detail, we analyzed
transendothelial electrical resistance (TEER) in an in
vitro BBB system of endothelial monocultures. Surpris-
ingly, cuprizone significantly decreased TEER after only
48 h that dropped further to about 80 ± 3% (mean ± SD)
of control values after 72 h (Fig. 2a). This effect was also
observed in the advanced BBB setup, in which endothe-
lial cells were co-cultured with primary astrocytes (Fig.
2b). Moreover, by immunostaining and expression ana-
lysis of primary endothelial cells, we observed reduced
protein and mRNA abundance of the tight junction pro-
tein occludin, and reduced Abcb1a mRNA of the ABCB1
(P-glycoprotein) efflux transporter, likely explaining the
decreased tightness of the barrier in vitro (Fig. 2c, d).
Abundance of mRNAs for the astroglial BBB mainten-
ance factor sonic hedgehog and for other tight junction
proteins, which were strongly downregulated in the cor-
pus callosum of cuprizone treated animals (Fig. 1a, d, e),
remained unchanged. Cuprizone treatment downregu-
lated occludin in the absence of inflammatory mediators,
whose expression in primary endothelial, astrocyte, and
microglial cultures were not induced by the cuprizone
challenge (Additional file 2: Figure S3e-g). Together,
these in vitro data suggest that cuprizone could directly
affect BBB constituents in vivo, even in the absence of
additional disease processes.
BBB dysfunction depends on local pathology
To test this, we treated mice for 5 weeks with cuprizone
as before and then analyzed the integrity of endothelial
tight junctions on cortical sections. The cortex develops
the demyelinating pathology later than the corpus callo-
sum (Additional file 2: Figure S1), as previously reported
[13, 23], allowing us to test if tight junction integrity is af-
fected before pathology exacerbates. In the cortex of
cuprizone treated animals and controls, staining intensity
and continuity of the tight junction proteins occludin and
(See figure on previous page.)
Fig. 1 Increased BBB permeability at 5 weeks cuprizone is mediated by downregulation of tight junction proteins. a, b Quantitative RT-
PCR analysis on dissected corpus callosum tissue samples from mice after 5 weeks cuprizone administration. Results show fold-change
values of individual animals (N = 4) normalized to the mean of untreated control animals (set to 1; N = 4–8) according to color code. a
Assessed were oligodendroglial genes (OL), astroglial and microglial markers (gliosis) and the endothelial markers. b Assessed were the
inflammatory markers as indicated. c Representative electron micrographs of the neurovascular junction in control and cuprizone exposed
animals. Arrowheads mark the separation between tight junctions of adjacent endothelial cells, and the asterisk points to split basement
membranes (bm) (AC, astrocyte, EC, endothelial cell, Scale bar: 100 nm) (d-e) Representative pictures of the corpus callosum of untreated control mice
and mice after 5 weeks cuprizone exposure immunostained for endothelial proteins as indicated (Scale bars: 20 μm). f Extravasation of the tracer FITC-
dextran (70 kDa) in mice fed cuprizone for 5 weeks (arrowheads) but not in control mice. DiD vessel paint mark vessel outline (Scale bars: 50 μm). g
Quantification of abundance of the tight junction proteins occludin (Ocln) and ZO1 from pictures as in (d) and (e) (N = 3 animals per group, Student’s
t-test, P < 0.001). h Density of blood vessels (GLUT1 or PECAM1 positive vessels per 10,000 square μm) in the corpus callosum of control mice (N = 5)
and mice after 5 weeks cuprizone (N = 4). Significance to control was evaluated by Student’s t-test (***P < 0.001). Total number of vessels per corpus
callosum (vessels / CC) as evaluated by PECAM1 or GLUT1 staining is similar in both treatment groups (right panel)
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ZO1 was similar (Fig. 3a, b), in contrast to the strongly re-
duced staining intensity in corpus callosum of the same
animals (Fig. 1d–g). Similarly, abundance of the tight junc-
tion protein claudin-5 (Fig. 3c) was not significantly re-
duced in cortex (90 ± 2% of controls in cortex lysates) of
cuprizone fed mice in comparison to corpus callosum ly-
sates (44 ± 4% of controls, n = 3, 2-way ANOVA P <
0.0001). Of note, abundance of claudin-5 in control ani-
mals was 69 ± 3% in cortex compared to corpus callosum
(n = 3, n = 3, 2-way ANOVA P < 0.0001), in line with a
study using porcine brain [41]. In accordance with the
mild gliosis (Additional file 2: Figure S1), vessel density
remained unchanged in cortex of cuprizone treated mice
compared to controls (Fig. 3d). These findings suggest that
in vivo, cuprizone alone is not sufficient to completely
abolish BBB integrity (see also below).
To substantiate the heterogeneity of BBB pathology
with another marker for NVU integrity, we compared
Aquaporin 4 (AQP4) distribution in corpus callosum
and cortex by immunostaining. AQP4 localization was
restricted to astrocyte endfeet in control animals and the
cortex of mice up to 5 weeks cuprizone (Fig. 3e, f ), sug-
gesting this brain region intact with respect to BBB in-
tegrity. In contrast, in the corpus callosum of these
mice, AQP4 displayed a diffuse staining pattern, and




Fig. 2 Cuprizone increases BBB permeability in vitro. Transendothelial electrical resistance (TEER) of (a) monocultures of primary endothelial cells
(EC) and (b) co-cultures of EC with astrocytes after 250 μM cuprizone for 24 h, 48 h and 72 h. Evaluation of significance was done by 2way ANOVA with
Sidak’s post test (*, P < 0.05; **, P < 0.01). Shown is one representative experiment but similar results were obtained in three additional experiments
(each N = 3–4 mice per condition). c Immunostaining of EC for occludin and PECAM1 that had been treated 250 μM cuprizone for 48 h (Scale bar:
20 μm) with quantification of % anti-occludin positive area on the right (N = 3 independent experiments, Student’s t-test, P > 0.01 **). d Quantitative
RT-PCR analysis on EC challenged with 250 μM cuprizone for 48 h. Results show mean fold changes of individual cultures (N = 3) normalized to vehicle
treated controls (set to 1). Significance to control was evaluated by unpaired Student’s t-test (P < 0.05 *)
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(2.71 ± 0.01 fold, n = 4 animals per group, P < 0.0001,
Student’s t-test), a condition also found in MS lesions [50]
and typical for cerebral edema in EAE. Together these
findings suggest that the morphological disturbances at
the BBB are associated with local active disease in cupri-
zone fed animals. This prompted us to investigate at
which disease state BBB dysfunction develops.
BBB impairment and edema are very early disease
processes
To determine the temporal progression of BBB impair-
ment, we simultaneously assessed the degree of BBB per-
meability and vasogenic edema after 3 days to 5 weeks
of cuprizone administration (Fig. 4a). Brain water as a
measure of edema was already significantly evident after
3 days cuprizone and progressively increased (Fig. 4b).
BBB dysfunction, as assessed by the biochemical extrac-
tion of extravasated Evans blue or sodium fluorescein
(Fig. 4a), developed with a similar time course as edema,
demonstrating a significant 1.25 ± 0.02 fold extravasation
(mean ± s.e.m., n = 4) after 3 days of cuprizone (Fig. 4c,
d). Because global edema values could be misleading, we
determined water content individually, in corpus callo-
sum and cortex of the same animals after 5 days of
cuprizone exposure. While the water content in the cor-






Fig. 3 BBB dysfunction depends on local pathology. a Representative pictures of the cortex of untreated control mice and mice after 5 weeks
cuprizone exposure immunostained for endothelial tight junction proteins as indicated co-labeled with the endothelial marker PECAM1 (Scale
bars: 20 μm). b Quantification of abundance of the tight junction proteins occludin (Ocln) and ZO1 from pictures as in (a). c Immunoblot detecting
claudin-5 in cortex (Ctx) and corpus callosum (CC) lysates from mice treated with cuprizone (cup) for 5 weeks and untreated controls. GAPDH shows
equal loading of protein. d Immunostaining and density of blood vessels (PECAM1 or GLUT1 positive vessels per square mm) in the cortex of control
mice (N = 5) and mice after 5 weeks cuprizone (N = 4). e Representative pictures of corpus callosum and cortex of untreated control mice and mice
after 5 weeks cuprizone immunostained for AQP4 (Scale bar: 20 μm). f Quantification of immunolabeling as depicted in (e) of N = 3–4 animals per
condition. Significance was evaluated by 1way ANOVA with Dunnett’s post test (***P < 0.001)
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range as in controls, the corpus callosum of cuprizone
treated animals displayed a 16.6 ± 0.5% water increase
(Fig. 4e, mean ± s.e.m., N = 4–5), a value typical for focal
edema [28]. Corresponding with these local differences
in edema, focal extravasation of fluorescent tracers in-
creased more than twofold in the corpus callosum but
only marginally in the cortex of cuprizone treated ani-
mals (Fig. 4f, g).
To assess how this regional heterogeneity of edema and
BBB permeability correlates with local pathology and glio-
sis in this early disease phase, we performed a series of
quantitative expression analyses on dissected corpus callo-
sum and cortex together with histopathological evaluation
of tissue sections, after 5 days of cuprizone. Expression of
marker proteins for astrocytes and microglia reflected the
mild histopathological changes (Fig. 4h, Additional file 1:
Table S3, Additional file 2: Figure S1). Despite reduced
Plp1 and Olig2 expression, mice lacked signs of demyelin-
ation and loss of oligodendrocytes, as reported previously
[13, 24]. The abundance of mRNAs of endothelial tight
junction proteins were only moderately downregulated in
cortex compared to corpus callosum, mirroring the
immunostaining data at 5 weeks of cuprizone exposure
(Fig. 4h, compare Figs. 1d-e, 3a). Expression of the ABCB1
transporter and associated caveolins as well as of the BBB
maintenance factor sonic hedgehog remained almost un-
affected in the cortex compared to untreated wild type
mice. It is possible that a direct effect of cuprizone con-
tributed to the residual downregulation of endothelial
markers and to the slight BBB hyperpermeability (Fig. 4g),
similar to our observations in vitro (compare Fig. 2). In
contrast, all markers for NVU integrity were strongly
downregulated in corpus callosum at this early time point
of cuprizone induced pathology.
Levels of the inflammatory mediators Il6, Il1b, Tnf,
and Ccl2 were strongly elevated in the corpus callosum
but only moderately increased in the cortex after 5 days





Fig. 4 Cuprizone induces early BBB dysfunction and edema. a Experimental procedure to measure BBB permeability by quantifying extravasation
of the tracers Evans blue (EB) and sodium fluorescein (NaFl), and edema (brain water). Tracers are i.v. injected, and mice are flushed with PBS after
4 h. The dissected brain is lyophilized (lyo). Brain water content (edema) is calculated from the weight difference of wet to lyophilized tissue. Tracers
are extracted, and fluorescence intensity quantified. b Brain water (g/g dry brain) in mice fed cuprizone for 3 days to 5 weeks as indicated, and
untreated controls (N = 4–5). Significance to control was evaluated by 1way ANOVA with Tukey’s post test (***P < 0.001). c, d Extravasated EB (N = 4–6)
and NaFl (N = 4) after cuprizone administration for 3 days to 5 weeks. Significance to control was evaluated by 1way ANOVA with Tukey’s post test
(**P < 0.01, ***P < 0.001). e Water content (g/g dry tissue) in dissected corpus callosum (CC) or cortex (Ctx) of mice fed cuprizone for 5 days or controls
(N = 4–5). Significance was determined by unpaired Student’s t-test for each brain region (***P < 0.001). Extravasated (f) EB (N = 4) and (g) NaFl (N = 5)
in dissected CC or Ctx of mice fed cuprizone for 5 days normalized to untreated controls. Significance to controls was evaluated by Student’s t-test (*P
< 0.05, ***P < 0.001). Quantitative RT-PCR analysis on dissected CC or Ctx from mice that received cuprizone for 5 days (N = 4) or control mice, evaluat-
ing cellular markers (h) and inflammatory mediators (i). Values of individual mice are shown as fold differences to the mean of N = 4–5 controls (set to
1) according to color code
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BBB integrity is already affected within the first days of
cuprizone exposure, coinciding with elevated levels of
inflammatory mediators but preceding overt demyelin-
ation and oligodendrocyte loss.
Reduced inflammation ameliorates BBB pathology
These findings prompted us to test directly whether de-
myelination and oligodendrocyte loss or local gliosis and
the secretion of inflammatory mediators correlate with
BBB dysfunction. Therefore, we used type 3 CXC che-
mokine receptor (CXCR3) deficient mice [26] that de-
velop demyelination in response to cuprizone as wild
type mice but show strongly reduced reactive gliosis and
expression of pro-inflammatory cytokines and chemo-
kines such as TNF, IL6 and CCL2 [32].
After 5 days of cuprizone, we found attenuated expres-
sion of markers for astrogliosis and microgliosis as well
as inflammatory mediators in CXCR3 deficient corpus
callosum compared to identically treated wild type ani-
mals (Fig. 5a, b). Expression of the oligodendroglial tran-
scription factor Olig2 and the myelin protein PLP1 was
ameliorated in CXCR3 deficient mice (Olig2, 3.86 ± 0.23
fold; Plp1, 2.28 ± 0.05 fold in CXCR3 knockout mice
compared to cuprizone fed controls), suggesting that the
oligodendroglial damage was slightly less severe at this
time point. Interestingly, the strong downregulation of
genes indicative of BBB dysfunction such as tight junc-
tion proteins and BBB maintenance factors was also
ameliorated in CXCR3 deficient animals (Fig. 5c). Re-
duced brain edema (Fig. 5d) and attenuated extravasa-
tion of fluorescent tracers (Fig. 5e, f ) in CXCR3 deficient
animals further support the hypothesis that pro-
inflammatory mediators contribute to BBB disruption in
response to cuprizone exposure.
Although CXCR3 is mainly expressed by microglial cells
in untreated mice [26], and also when mice are challenged
with cuprizone (Additional file 2: Figure S4), the cell type
responsible for establishing the cytokine milieu during ini-
tial cuprizone pathology that contributes to BBB dysfunc-
tion is unknown. Therefore, we acutely isolated microglia,
astrocytes, oligodendrocytes, and endothelial cells from
wild type and CXCR3 deficient mice after 5 days of cupri-
zone treatment and from untreated wild type control ani-
mals, and analyzed mRNA abundance of Tnf, Il1b, Il6,
and Ccl2. We chose these inflammatory mediators be-
cause their expression pattern correlates with the extent
of BBB disturbances: after 5 days of cuprizone, their ex-
pression levels were most strongly increased in corpus cal-
losum of wild type mice, moderately increased in the
corpus callosum of CXCR3 mutant animals, and only
weakly upregulated in the cortex of wild type animals
compared to untreated wild type controls (compare Figs. 4i
and 5b). Oligodendroglia did not significantly contribute
to the cytokine and chemokine profile after 5 days of
cuprizone and surprisingly, neither did microglia (Fig. 5g,
Additional file 1: Table S4). Endothelial cells showed mod-
erate upregulation of cytokine and chemokine expression.
In contrast, we identified astrocytes as the major source of
all tested pro-inflammatory mediators at this early disease
phase (Fig. 5g). Further, the increased expression of in-
flammatory molecules was completely abolished in astro-
glia of CXCR3 deficient mice, suggesting that microglial
CXCR3 signaling induces astroglial upregulation of cyto-
kines and chemokines in response to cuprizone.
Discussion
BBB impairment is considered as an important feature in
MS pathologies, but the causal relation to disease pro-
cesses during initial lesion formation and its impact on
disease activity is unknown. In the current study we ana-
lyzed the temporal and spatial relationship of BBB dys-
function to gliosis, expression of inflammatory mediators,
and demyelinating pathology in the cuprizone mouse
model of demyelination. By using wild type and CXCR3
deficient mice, we demonstrate that BBB impairment is
most pronounced in the corpus callosum of wild type ani-
mals, to a lesser extent in the corpus callosum of CXCR3
deficient mice, and only minimally in the cortex of wild
type mice in the initial disease phase before the onset of
demyelination. Our data indicate that IL6, IL1β, TNF, and
CCL2 are the most likely candidates to contribute to BBB
dysfunction in the cuprizone model.
It is well known that TNF, IL6, IL1β and CCL2 can
each induce downregulation of endothelial tight junction
proteins in vitro and induce BBB hyperpermeability in
vivo [14, 20, 43, 47, 53, 58]. Enhanced paracellular leak-
age is mediated by downregulation of mRNA of tight
junction proteins as shown in our study and in a model
of bacterial infection [40]. Pro-inflammatory cytokines
induce signaling cascades that can lead to downregula-
tion of stabilizing factors such as sonic hedgehog [3, 58],
to activation of effector proteins such as matrix metallo-
proteinases [33], and to the formation of reactive oxygen
species [47]. In our experimental paradigm, increased
expression of nitric oxide synthases and downregulated
sonic hedgehog signaling likely contributed to tight junc-
tion disruption. In addition, all three cytokines have the
ability to reduce ABCB1 mediated efflux, facilitating
transendothelial passage [25]. We found downregulation
of ABCB1 not only in cuprizone fed mice but also in
endothelial cultures in the absence of inflammatory me-
diators, suggesting that cuprizone directly affected trans-
endothelial passage.
Although it is generally assumed that microglia secrete
the majority of effector molecules, our data show that in
the initial disease phase of the cuprizone model micro-
glia do not themselves contribute to the upregulation of
IL6, IL1β, TNF or CCL2; rather astrocytes (with a
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moderate participation by endothelial cells) are the main
source of these pro-inflammatory cytokines and chemo-
kines. At later disease stages, however, microglia sub-
stantially add to the production of inflammatory factors
[57]. Astrocytes participate in recruiting microglia as
shown in mouse mutants with acutely depleted astro-
cytes [52]. They promote recovery and repair in mouse
models of remyelination but can also facilitate demyelin-
ation in acute active lesions of MS patients [11, 31, 35].
Whether astrocytes are the main source of disease pro-
moting factors in presymptomatic MS patients before
the onset of demyelination is unknown. We demonstrate
that astrocytes, which are intimately involved in regulat-
ing BBB function via their endfeet, create a local inflam-
matory milieu that likely participates in destabilizing
BBB integrity. Although cuprizone by itself does not in-
duce astroglial, endothelial, or microglial expression of
any of the tested pro-inflammatory mediators in vitro, it
mildly affects metabolic activity in endothelial cells (this
study) in addition to mature oligodendrocytes [10]. Death
of oligodendrocytes in vivo is enforced by local glial acti-
vation [27]. We hypothesize that also vascular cells con-
tribute to this complex crosstalk that lead to BBB
impairment and demyelination in the cuprizone model.
Paracellular influx of fluid because of BBB disruption is
the leading cause of vasogenic edema [54], also found in
MS and inflammatory models of MS [9, 48, 60]. Edema
correlates with increased AQP4 abundance and its mislo-
calization from (frequently hypertrophic) astroglial endfeet
that is associated with altered basement membrane
morphology in EAE [2, 60]. We also observed loosening
of the astrocytic and endothelial basement membranes in
the cuprizone model, emphasizing similar pathogenic pro-
cesses in these disparate models of MS. Although it is
well-known that cuprizone intoxication causes spongiform






Fig. 5 CXCR3 KO ameliorates BBB pathology. a-c Quantitative RT-PCR analysis on dissected corpus callosum tissue samples from wild type (red)
or CXCR3 deficient (blue) mice after 5 days cuprizone administration or untreated control mice. Results are expressed as mean fold change of N = 3–4
mice ± s.e.m., normalized to untreated wild type control animals (set to 1; gray line, N = 5). Assessed were (a) cellular markers, (b) cytokines
and chemokines, and (c) endothelial and BBB promoting markers as indicated. Significance between WT mice and CXCR3 mice was evaluated
by Student’s t-test for each individual gene (*P < 0.05, **P < 0.01, ***P < 0.001). d-f Brain water (d, g/g dry brain), of extravasated EB (e), and NaFl (f) in
untreated wild type controls (white, N = 3–4), and wild type (red, N = 3–4) or CXCR3 deficient (blue, N = 3) mice exposed to cuprizone for 5 days.
Significance to control was evaluated by 1way ANOVA with Tukey’s post test (*P < 0.05, **P < 0.01, ***P < 0.001). g Quantitative RT-PCR on isolated cells
as indicated from brain of from WT or CXCR3 deficient mice after 5 days cuprizone administration or untreated control mice. Results show fold-change
values according to color code of individual animals (N = 3) normalized to the mean of untreated control animals (set to 1; N = 5)
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ignored, potentially because of the absence of massive
BBB disruption in this model [8, 12, 30]. For the first time,
to our knowledge, we quantified edema in the cuprizone
model and found that increased brain water content was
most pronounced during overt demyelination. Import-
antly, edema was already obvious before the onset of de-
myelination and oligodendrocyte loss.
In agreement with others [13, 23], we observed
marked regional differences in disease manifestation in
the cuprizone model. Interestingly, similar to our obser-
vation in the cortex of cuprizone treated animals, cor-
tical pathology in MS also differs substantially from
white matter lesions; the former comprising only mild
gliosis and modest alteration of tight junctions [21, 56].
In addition to the differences in tissue architecture and
expression profiles of neural cells [22, 38], the regional
heterogeneity of pathology could also be influenced by
differences in vasculature. As we show here in accord-
ance with previous studies, vessel density in gray matter
is about double of that in white matter, and steady state
levels of tight junction proteins are lower [41]. Together,
these differences likely modify BBB properties, which
might play a role in rendering cortical MS lesions less
susceptible to disease exacerbation.
Does an impaired BBB directly affect the course of de-
myelinating disease? Chronic upregulation of inflammatory
mediators directly impairs BBB integrity and can induce de-
myelinating pathology [46]; conversely, their genetic or
pharmacological reduction can improve BBB function but
their role in modulating severity of demyelinating disease in
the context of EAE or cuprizone is less clear [7, 16, 36, 39].
The induction of an inflammatory milieu and BBB impair-
ment have been uncoupled by inhibition of nitric oxide syn-
thesis in the cuprizone model [29] or by targeted
overexpression of claudin-1 in EAE [44] that both support
BBB tightness but presumably do not (directly) affect ex-
pression of pro-inflammatory molecules. In these experi-
mental paradigms, clinical symptoms of treated/transgenic
mice were ameliorated, suggesting that endothelial integrity
might contribute to disease expression. In a study with 39
patients with neuromyelitis optica, BBB leakage in normal
appearing white matter correlated with progression to MS
pathology [17]. We show here that BBB dysfunction and
edema occurred before demyelination, suggesting that de-
myelination itself does not cause BBB damage. We specu-
late that BBB dysfunction might serve as a predictive
marker for local disease activity.
Conclusions
In summary, our data show that in vitro cuprizone dir-
ectly increases BBB permeability mediated by downregu-
lation of tight junction proteins. In vivo, astroglial
derived pro-inflammatory cytokines create a local in-
flammatory milieu that likely further destabilizes local
BBB integrity and induces edema. We envision that glial
activation and production of pro-inflammatory media-
tors in any neurological disorder destabilizes BBB integ-
rity. In demyelinating disease, these presymptomatic
disease processes might have prospective value for future
disease activity and disease progression.
Additional files
Additional file 1: Table S1. Primer sequences used for gene expression
analyses. Table S2. Quantification of gene expression in corpus callosum.
Table S3. Quantification of gene expression in cortex. Table S4.
Quantification of gene expression in acutely isolated cells. (PDF 70 kb)
Additional file 2: Figure S1. Time course of cuprizone induced
pathology in corpus callosum and cortex. (a) Representative pictures of
the corpus callosum (CC) and the cortex (Ctx) of untreated control mice
and mice after cuprizone exposure for 5 days and 5 weeks assessing
myelination (Gallyas silver impregnation), mature oligodendrocytes (CAII),
activated microglia (MAC3), and astrocytes (GFAP) (Scale bars: 20 μm)
with quantification in (b). Each bar represents the mean value of N = 3–4
animals per condition with individual data points. Significance to control
was evaluated by 1way ANOVA with Tukey’s post test (*P < 0.05, **P <
0.01, ***P < 0.001). Figure S2. Endothelial junctions in mice after 5 weeks
cuprizone. Electron microscopic images of capillaries showing
disconnected endothelial and astroglial basement membranes (a,
arrowheads), an affected endothelial cell (b) with electron light cytoplasm
and focal disruption of endothelial tight junctions (a, b, arrow). Astroglial
endfeet often appeared swollen (c, green). Scale bars: 2 μm (AC,
astrocyte; EC, endothelial cell; EF, astroglial endfoot; M, microglia/
macrophage; P, pericyte). Figure S3. Cuprizone affects endothelial cells
but not astrocytes in vitro. Cell vitality measurements (WST1 assays) of
primary (a, c) endothelial cells or (b, d) astrocytes after exposure to
vehicle (0, white) or to increasing concentrations of cuprizone (50–
500 μM, red) for 24 h (a, b) or with 250 μM cuprizone for 72 h (c, d) (N =
5 per condition). Incubation with 20 μM peroxide for 4 h induced cell
death and was used as positive control (N = 3, +). Significance to vehicle
was evaluated by (a, b) 1way ANOVA with Dunnett’s post test or (c, d)
Student’s t-test (**P < 0.01, ***P < 0.001). (e, f, g) Quantitative RT-PCR ana-
lysis on cultured primary endothelial cells (e), astrocytes (f), and microglia
(g) challenged with 250 μM cuprizone for 48 h. Results show mean fold
change with individual data points of N = 3 cultures normalized to ve-
hicle control (set to 1). Figure S4. CXCR3 is expressed by microglia in
cuprizone fed mice. Direct GFP fluorescence of CXCR3GFP/GFP mice to-
gether with immunolabeling of cell type specific markers for microglia
(Iba1), astrocytes (GFAP), or oligodendroglia (Olig2) in the corpus callo-
sum and cortex in CXCR3 deficient mice that had been exposed to cupri-
zone for 5 days (Scale bars: 20 μm). (PDF 19968 kb)
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